Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis’ (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.